Answer the following statements true (T) or false (F)
1. The personal representative is also called the beneficiary.
2. Administrators are personal representatives that have been appointed by the state if the decedent hadn’t executed a will.
3. If an alternative personal representative is not named in the trust, the beneficiary receiving the second most amount in monetary assets will then become the personal representative if the initial representative can’t or won’t fulfill their duties.
4. An administrator ad litem is appointed when there is a will contest, and when the court hearing the contest believes that the personal representative should not handle the administration of the estate during the pendency of the suit.
5. A personal representative or administration will take an oath stating that he or she will faithfully fulfill his or her fiduciary duties.
1. False
2. True
3. False
4. False
5. True
You might also like to view...
All captioners are known by the same title regardless of their working situation
a. True b. False
Paralegal Mara has been working for a plaintiff's personal injury firm for 4 years and is looking for a change. She's thinking about a job with a real estate firm, but she has no experience in that area. Options for Mara are
A) reading some real estate practice manuals and articles about the duties that paralegals have in that area of the law. B) going back to school to take some courses in real estate and related topics. C) taking some continuing legal education courses through her local paralegal or bar organization. D) taking some courses at school, or through continuing education, and doing some independent reading in practice manuals and other professional publications.
If an examining attorney finds defects in a patent application, he or she will usually issue a[n] ______ to the applicant who will then respond to the USPTO comments and objections.
Fill in the blank(s) with the appropriate word(s).
The government of India is concerned that the holder of a patent for a critically important cancer-treating drug is not producing sufficient quantities of the drug at affordable prices to treat patients in India. What might the government do?
What will be an ideal response?